Eurasian Journal of Medicine and Oncology

Eurasian Journal of Medicine and Oncology is a peer-reviewed open access journal that publishes research across oncology and general medicine for an international readership, and it has appeared since 2017.《欧亚医学与肿瘤学杂志》是一份面向国际读者的同行评议开放获取期刊，刊载肿瘤学与综合医学领域的研究，自 2017 年起发行至今。

Its remit joins the whole of medicine to the study and treatment of cancer, and the stated ambition is to link laboratory findings with what clinicians can use at the bedside.该刊的定位把综合医学与癌症的诊疗研究连在一起，其公开写明的目标是把实验室发现与临床一线可用的手段接上。

Manuscripts are accepted in English only, and the journal offers original research articles with reviews, editorials, letters to the editor and perspectives, many of them gathered into guest edited special issues.稿件只接受英文投稿，期刊栏目包括原创研究、综述、社论、致编辑函与观点文章，其中不少归入客座主编主持的专刊。

Scope

• The oncology section covers medical, surgical, radiation and paediatric oncology, and it also takes in cancer epidemiology, prevention and translational research.肿瘤学板块涵盖肿瘤内科、肿瘤外科、肿瘤放射与肿瘤儿科，癌症流行病学、预防与转化研究也在其内。

• Molecular work on disease mechanisms sits inside that scope, with oncogenes, metastasis and viral oncology named alongside the clinical side of the discipline.疾病机制的分子研究也在其内，癌基因、转移与病毒肿瘤学与肿瘤学的临床面向被一并列出。

• Clinical oncology and chemotherapy form part of the same remit, and the pages carry work on the drugs used against tumours and on the ways tumours resist them.临床肿瘤与化疗属同一范围，期刊刊载抗肿瘤药物方面的研究，也刊载肿瘤产生耐药机制的成果。

• The medicine section reaches every branch of the discipline, from internal medicine and the surgical specialties to diagnosis, treatment and the technology used in both.医学板块覆盖各分支，从内科与外科各专科，到诊断、治疗以及两者用到的技术手段。

• Cardiology, neurology, infectious diseases, public health and preventive medicine are listed as the areas of internal medicine the journal wants to hear from.心脏病学、神经病学、传染病学、公共卫生与预防医学被列为该刊希望收到稿件的内科方向。

• Dentistry appears beside medicine in the stated scope, and dental research has been planned as a themed special issue.牙科与医学并列写进宗旨范围，牙科研究已被安排成主题专刊。

• The stated aim is to bridge basic research and clinical application, so a mechanistic study and a treatment outcome study are expected to sit close together in the same journal.宗旨写明要在基础研究与临床应用之间架桥，机制研究与疗效研究因此可以在同一份刊物里彼此靠近。

• Recent volumes show the oncology side at work across breast, gastrointestinal, lung, prostate, gynaecological and haematological cancers, and also glioma and other brain tumours.近年的卷册里，肿瘤学一面横跨乳腺、消化道、肺、前列腺、妇科与血液系统癌症，胶质瘤等脑肿瘤也在其中。

• Imaging occupies a large share of the clinical work, with radiomics, texture analysis, molecular imaging and image based machine learning all represented in recent papers.影像在临床研究中占很大比重，近期论文里可见影像组学、纹理分析、分子影像与基于影像的机器学习。

• One strand treats cancer metabolism, the immune microenvironment and multi omics data, often with single cell, spatial or proteomic measurements behind the conclusions.另有一支内容处理癌症代谢、免疫微环境与多组学数据，结论背后常是单细胞、空间或蛋白组层面的测量。

• Methods work has leaned on artificial intelligence, including prediction models built with machine learning and explainability tools such as SHAP, and on Mendelian randomization for causal questions.方法学方面的人工智能用得不少，包括以机器学习搭建的预测模型与 SHAP 这类可解释方法，因果问题则常用孟德尔随机化。

• Drug delivery, bio engineered polymers, organ on a chip platforms and phytotherapy fill the themed issues, which points to the more laboratory facing end of the journal.专刊里还出现药物递送、生物工程聚合物、器官芯片平台与植物药研究，指向该刊偏实验室的一面。

• Health services and uptake in particular regions form a steady line of work, with recent papers on vaccination readiness among students and on the burden carried by defined populations.服务体系与特定地区的接受度也是稳定的题材，近期有学生群体疫苗接种意愿与特定人群疾病负担方面的论文。

• Case reports and imaging series are accepted beside the larger studies, and the journal is open to work from the fields of pharmacology, pathology, radiology, immunology, genetics and epidemiology.病例报告与影像系列与大样本研究一并收稿，刊物对药理学、病理学、放射学、免疫学、遗传学与流行病学领域的成果同样开放。

History

• The journal was launched in August 2017 by Kare Publishing of Istanbul, and its first volume ran under that imprint for the years that followed.该刊 2017 年 8 月由伊斯坦布尔的 Kare Publishing 创刊，其后若干年都以这一出版标识发行。

• Scopus took the journal in January 2019, and two years later it entered the Emerging Sources Citation Index of the Web of Science Core Collection.Scopus 在 2019 年 1 月收录了它，两年后该刊进入 Web of Science 核心合集的 Emerging Sources Citation Index。

• In October 2024 the journal moved to AccScience Publishing, an open access house based in Singapore that had already taken over a group of titles from other publishers.2024 年 10 月该刊转到 AccScience Publishing，这是一家设在新加坡的开放获取出版机构，此前已从别的出版方接手一批刊物。

• The change of publisher also moved the platform, the manuscript system and the archive, and the former address of EJMO at ejmo.org no longer serves the journal.换出版方也带来了平台、稿件系统与存档的整体迁移，《EJMO》的旧址 ejmo.org 已不再提供该刊内容。

• The electronic number is 2587-196X and the print number 2587-2400, and this pair of numbers stands in the footer of every page.电子版编号为 2587-196X，印本号为 2587-2400，这一组编号印在刊站每一页的页脚上。

• Under the new owner the journal became fully open access, with articles free to read from the day they appear and a Creative Commons licence that leaves the copyright with the authors.在新东家手里该刊转为完全开放获取，论文发表当天即可免费阅读，所用许可把版权留给作者。

• Indexing has continued to widen since the move, with Gale added in July 2025, CAS in December 2025 and Embase in September 2026.转社之后收录范围继续扩大，2025 年 7 月加入 Gale，2025 年 12 月加入 CAS，2026 年 9 月加入 Embase。

• The first impact factor announced under the new publisher was 0.7 in June 2025, when the title sat in the third quartile of general medicine and the fourth of oncology.该刊在新出版方名下公布的第一个影响因子是 2025 年 6 月的 0.7，当时位于综合医学第三区与肿瘤学第四区。

• The figure in the 2025 citation report is 1.3, with a five year value of 0.9 and a journal citation indicator of 0.19, and the title now sits in the second quartile of general and internal medicine.2025 年版引证报告给出的数值是 1.3，五年指标 0.9，期刊引证指标 0.19，该刊现居医学总论与内科学类的第二区。

• The same report counts 256 citations in total and 68 articles published in the year, with a citing half life of 2.9 years and 87.63 per cent of the output counted as gold open access.同一份报告记录总被引 256 次，年发文 68 篇，引用半衰期 2.9 年，另有 87.63% 的论文计入金色开放获取。

• One volume appears each year, and the tenth volume covers 2026 with its fifth issue already open, while articles also appear ahead of the issue they belong to.每年出卷，第 10 卷对应 2026 年，其中第 5 期已经上线，另有先行发表的论文排在期次之前。

• The paper archive is preserved in Portico, and the Scopus source identifier for the title is 21101061946, which keeps the citation record continuous across the change of publisher.论文存档由 Portico 保存，该刊在 Scopus 的源标识为 21101061946，换社前后的引文记录因此得以接续。

• The national medical library in the United States lists the title from its first year, with PubMed holding selected citations only and the abbreviated title Eurasian J Med Oncol.美国国立医学图书馆自创刊年起即收录该刊，PubMed 只保留部分引文，标准缩写为 Eurasian J Med Oncol。

Editors

• The journal is run by three editors in chief, and the first of them is Bernd Kaina, a professor of toxicology at the University Medical Center of the Johannes Gutenberg University Mainz.该刊由三位主编主事，第一位是（Bernd Kaina），任美因茨约翰内斯·古腾堡大学医学中心毒理学教授。

• His research concerns the DNA damage response, repair of critical lesions, mutagenesis and the resistance of glioblastoma cells to alkylating drugs.他的研究涉及 DNA 损伤反应、关键损伤修复、致突变，以及胶质瘤细胞对烷化剂的耐受。

• The second editor in chief is Hilmi Kodaz of the Department of Medical Oncology at Acibadem Eskisehir Hospital in Eskisehir, Turkey.第二任主编是（Hilmi Kodaz），供职于土耳其埃斯基谢希尔的 Acibadem Eskisehir Hospital 肿瘤内科。

• A third editor in chief, Mingzhu Yin, completes the top editorial team, and the site lists each of the three with an individual contact address.第三任主编是（Mingzhu Yin），三人组成最高一级的编辑阵容，刊站为每位主编列出各自的联系地址。

• Around them sits an editorial board of one hundred and forty members or so, and a chart on the site groups those members by the country they come from.其外围是一个一百四十余人的编委会，站上用图表按委员的来源国别给他们分组。

• The countries represented run from China and Turkey through Germany, Italy, France, Russia, Greece, Romania and South Korea to Portugal, Poland, Denmark, the Netherlands, Ukraine, Australia, Bangladesh, Cyprus and Oman.委员来源国从中国、土耳其一路排到德国、意大利、法国、俄罗斯、希腊、罗马尼亚与韩国，也包括葡萄牙、波兰、丹麦、荷兰、乌克兰、澳大利亚、孟加拉国、塞浦路斯与阿曼。

• Board members come with their own research interests on file, such as Xianbin Kong on immunotherapy and colorectal cancer and Shuai Mu on nanomedicine and biological imaging.名单上的委员各附研究兴趣，（Xianbin Kong）写免疫治疗与结直肠癌，（Shuai Mu）写纳米医学与生物成像。

• Others include Ludovica Pepe of the University of Messina on pathology and immunohistochemistry, and Zhen Yang of Peking University People's Hospital on stem cells and tissue engineering.其余名单里有（Ludovica Pepe），来自墨西拿大学，研究方向是病理学与免疫组化；还有（Zhen Yang），来自北京大学人民医院，写干细胞与组织工程。

• Review is double blind, so authors and reviewers stay unnamed to each other through the decision, and originality is checked with CrossCheck before a paper is accepted.评审采用双盲，投稿人与审稿人在决定过程中彼此匿名，录用前还用 CrossCheck 查重。

• The journal follows the code of conduct of the Committee on Publication Ethics, and it keeps a zero tolerance line on plagiarism, data fabrication and image manipulation.该刊遵循出版伦理委员会的道德行为准则，对剽窃、数据造假与图像篡改采取零容忍立场。

• Guest editors are invited to shape themed issues, and recent examples include collections on natural compounds for cancer prevention and on atherosclerosis and cancer read through somatic evolution.客座主编受邀策划主题专刊，近年的例子有癌症预防的天然化合物那一辑，以及从体细胞演化角度解读动脉粥样硬化与癌症的合集。

• Manuscripts go in through the publisher's own submission system, where authors sign in with an email address or an ORCID iD, and the journal also keeps pages for author awards and for online seminars.稿件经出版方自有的投稿系统提交，作者可用邮箱或 ORCID iD 登录，该刊另设作者奖励与在线研讨等页面。